Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

Loukas F Kontovinis; Konstantinos T Papazisis; Panagiota Touplikioti; Charalambos Andreadis; Despoina Mouratidou; Alexandros H Kortsaris

doi:10.1186/1471-2407-9-82

Download references

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

Loukas F Kontovinis, Konstantinos T Papazisis^*, Panagiota Touplikioti, Charalambos Andreadis, Despoina Mouratidou and Alexandros H Kortsaris

* Corresponding author: Konstantinos T Papazisis kpapazisis@the.forthnet.gr

BMC Cancer 2009, 9:82 doi:10.1186/1471-2407-9-82

Include	Article citation and all cited references Cited references only Article citation only
Format	EndNote, Zotero or Papers Reference Manager Refworks BibTeX

BMC Cancer

Viewing options

Associated material

Tools

Share this article

Download references

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers

BMC Cancer

Viewing options

Associated material

Related literature

Cited by

Other articles by authors

Related articles/pages

Tools

Share this article

Download references

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers